<DOC>
	<DOCNO>NCT02250872</DOCNO>
	<brief_summary>Cisplatin potent chemotherapeutic agent , however , nephrotoxicity manifest acute kidney injury ( AKI ) often limit applicability . Dipeptidylpeptidase-4 ( DPP4 ) inhibitor well know improve glucose intolerance augmentation endogenous glucagon like peptide ( GLP-1 ) glucose-dependent insulinotropic peptide ( GIP ) . DPP4 inhibitor also potential anti-apoptotic renoprotective effect mouse model cisplatin-induced AKI . This single-center , randomize , double-blind , parallel-group , placebo-controlled , prospective study investigate renoprotective effect DPP4 inhibitor cisplatin-induced AKI . A total 182 patient , schedule treat cisplatin , recruit randomly assign either Gemigliptin placebo group . Subjects take study drug 8 day start one day cisplatin treatment . Serum creatinine ( Cr ) estimate glomerular filtration rate ( eGFR ) measure 7 day cisplatin treatment .</brief_summary>
	<brief_title>Effects DPP4 Inhibitor Cisplatin Induced Acute Kidney Injury</brief_title>
	<detailed_description>This study investigate possible renoprotective effect DPP4 inhibitor cisplatin induce acute kidney injury .</detailed_description>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>age &gt; 18 year cancer patient treat intravenous cisplatin write consent Diabetes mellitus Chronic kidney disease stage IVV ( eGFR &lt; 30ml/min/1.73m2 ) History transplantation History acute kidney injury randomization Use nephrotoxic agent non steroidal antiinflammatory drug , aminoglycosides , colistin , vancomycin Receiving contrast medium last 72 hour Liver disease ( bilirubin &gt; 2 mg/dl , transaminase level &gt; 2.5 time upper limit normal ) Active infection Patients high risk dehydration owe poor oral intake High blood pressure ( &gt; 180/110 mmHg despite antihypertensive medication ) Hypersensitivity Gemigliptin excipients Low compliance Gemigliptin treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Cisplatin</keyword>
	<keyword>Nephrotoxicity</keyword>
	<keyword>Gemigliptin</keyword>
	<keyword>DPP4 inhibitor</keyword>
</DOC>